PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
142.24%
Some net income increase while VET is negative at -47.47%. John Neff would see a short-term edge over the struggling competitor.
-4.31%
Negative yoy D&A while VET is 5.48%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
2466.67%
Well above VET's 18.60% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-13.64%
Negative yoy SBC while VET is 10.59%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
183.80%
Slight usage while VET is negative at -161.92%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
183.80%
Some yoy usage while VET is negative at -161.92%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-12.28%
Negative yoy while VET is 227.02%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-18.66%
Both yoy CFO lines are negative, with VET at -16.07%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-9.59%
Negative yoy CapEx while VET is 63.94%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-2816.67%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-112.13%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
1373.68%
Liquidation growth of 1373.68% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-52.56%
Both yoy lines negative, with VET at -160.83%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-233.86%
Both yoy lines negative, with VET at -0.04%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
68.51%
We repay more while VET is negative at -411.45%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.